Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Journal: Cell Stem Cell

Published: 2019-08-27

DOI: 10.1016/j.stem.2019.08.004

Affiliations: 16

Authors: 44

Go to article
Institutions Share
UCLA Department of Microbiology, Immunology and Molecular Genetics (MIMG), United States of America (USA) 0.48
UCLA Department of Medicine, United States of America (USA) 0.18
UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research (BSCRC), United States of America (USA) 0.08
UCLA Jonsson Comprehensive Cancer Center (JCCC), United States of America (USA) 0.04
UCLA Department of Molecular and Medical Pharmacology (DMMP), United States of America (USA) 0.04
UCLA Department of Pediatrics, United States of America (USA) 0.04
UCLA Ahmanson Translational Imaging Division (ATID), United States of America (USA) 0.03
Department of Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, United States of America (USA) 0.02
Institute for Systems Biology (ISB), United States of America (USA) 0.02
UCLA Department of Pathology and Laboratory Medicine, United States of America (USA) 0.02
UCLA Molecular Biology Institute (MBI), United States of America (USA) 0.02
UCLA Department of Biostatistics, United States of America (USA) 0.01
Parker Institute for Cancer Immunotherapy, United States of America (USA) 0.01
UCLA School of Nursing, United States of America (USA) 0.01
UCLA AIDS Institute, United States of America (USA) 0.01

Return